MarketLens

Thermo Fisher Scientific's C-Suite Selling Tests a Fully-Priced Growth Story

2 weeks ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Why is Thermo Fisher Betting Big on Clinical Trial Data

5 months ago

Thermo Fisher's Executive Sales: A Calculated Monetization Amidst Strong Performance

4 weeks ago

Has Avantor's Q4 Report Fully Priced In the Bad News

6 months ago

Halozyme's Record Quarter Is Fully Priced for Its Royalty Engine's Limits

2 weeks ago

How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends

Thermo Fisher is expanding bioproduction, AI tools, and clinical data capabilities to drive growth, though execution remains key amid intensifying competition.

TMO

Stock News•1 months ago

Acumen Wealth Advisors LLC Sells 2,166 Shares of Thermo Fisher Scientific Inc. $TMO

Acumen Wealth Advisors cut its Thermo Fisher Scientific holdings by 14.7% in Q1, selling 2,166 shares to 12,562, per a 13F filing.

TMO

Stock News•1 months ago

Caris Life Sciences: Disrupting Cancer Screening And Therapy Selection

Caris Life Sciences is rated a 'Buy' at ~$16.5, with a $22.3 fair value estimate implying ~35% upside, after its proprietary WES/WTS/WGS technology and data advantage drove 23%-26% estimated 2026 reve...

CAI

Stock News•1 months ago

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026

Thermo Fisher Scientific will release Q2 2026 results before market open on July 23, 2026, followed by an 8:30 a.m. ET conference call to discuss financial performance and future expectations.

TMO